Our review focused solely on MAPT mouse models of tauopathy, excluding research conducted in multitransgenic AD models, models that have tau pathology resulting from mutations in non‐MAPT genes, mouse models with comorbid pathology, models using tau protein injections, and non‐mouse models. This evidence concerns the gene MAPT and Alzheimer disease.